Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1.-11. (Canceled)

12. (New) A composition comprising:

at least one antibody selected from the group consisting of: anti-MSRV/HERV-W Env-SU antibodies, anti-TLR4 antibodies capable of binding specifically to the soluble fraction of the MSRV/HERV-W Env protein, anti-TLR4 antibodies capable of binding specifically to the TLR4 receptor for the soluble fraction of the MSRV/HERV-W Env protein, and mixtures thereof, wherein said at least one antibody inhibits the pro-inflammatory cascade induced by the activation of MSRV/HERV-W; and

a pharmaceutically acceptable carrier.

13. (New) The composition of claim 12, further comprising a pharmaceutically acceptable vector.

14. (New) The composition of claim 12, wherein the at least one antibody comprises at least one anti-MSRV/HERV-W Env-SU antibody and at least one anti-TLR4 antibody capable of binding specifically to the soluble fraction of the MSRV/HERV-W Env protein or anti-TLR4 antibody capable of binding specifically to the TLR4 receptor for the soluble fraction of the MSRV/HERV-W Env protein.

15. (New) The composition of claim 12, wherein the anti-MSRV/HERV-W Env-SU antibody is selected from the group consisting of: 3B2H4, 13H5A5, and 3H10F10, and wherein the anti-TLR4 antibody is HTA125.

16. (New) A method of treating a pathology associated with MSRV/HERV-W, comprising administering to an individual having said pathology the composition of claim 12,

wherein the at least one antibody is present in an amount sufficient to inhibit the pro-inflammatory cascade induced by the activation of MSRV/HERV-W.

17. (New) The method of claim 16, wherein the pathology associated with MSRV/HERV-W is multiple sclerosis or schizophrenia.

18. (New) A method of inhibiting the pro-inflammatory cascade induced by the activation of MSRV/HERV-W, comprising administering to an individual in need thereof a composition comprising at least one antibody selected from the group consisting of: anti-MSRV/HERV-W Env-SU antibodies, anti-TLR4 antibodies capable of binding specifically to the soluble fraction of the MSRV/HERV-W Env protein, anti-TLR4 antibodies capable of binding specifically to the TLR4 receptor for the soluble fraction of the MSRV/HERV-W Env protein, and mixtures thereof, and a pharmaceutical carrier.

19. (New) The method of claim 18, wherein the at least one antibody comprises at least one anti-MSRV/HERV-W Env-SU antibody and at least one anti-TLR4 antibody capable of binding specifically to the soluble fraction of the MSRV/HERV-W Env protein or anti-TLR4 antibody capable of binding specifically to the TLR4 receptor for the soluble fraction of the MSRV/HERV-W Env protein.

20. (New) The method of claim 18, wherein the anti-MSRV/HERV-W Env-SU antibody is selected from the group consisting of: 3B2H4, 13H5A5, and 3H10F10, and wherein the anti-TLR4 antibody is HTA125.

21. (New) A method of determining the state of reactivity of blood mononuclear cells from individuals suffering from multiple sclerosis or schizophrenia, comprising assaying cellular cytokines selected from the group consisting of: IL-6, IL12-p40, and TNF-α, and assessing cellular expression of MSRV/HERV-W to determine the state of reactivity.

22. (New) An antibody selected from the group consisting of: 3B2H4, 13H5A5, and 3H10F10.